FDA explores power of regulatory prayer

News & Politics

Revere reports that the FDA turning a blind eye to the sale of Miracle II Neutralizer. Formerly an industrial cleanser and degreaser, Miracle II is taking on new commercial life as a patent medicine recommended for use in the eyes (amongst other places) and touted as a treatment AIDS (amongst other conditions).

The FDA can't rule out the possibility that Miracle II is contaminated with bacteria. The agency warned parent company Tedco about their untested and potentially deadly product back in 2003, but Miracle II remains on the shelves.

According to the official website, "Miracle II: Not everyone who believes in God uses Miracle II, but everyone who uses Miracle II believes in God."

Revere says, "And if you believed in Miracle II it might be right, because you'd believe in anything. And if you used Miracle II, you might be slated for some face time with Saint Peter."

[Effect Measure]

Understand the importance of honest news ?

So do we.

The past year has been the most arduous of our lives. The Covid-19 pandemic continues to be catastrophic not only to our health - mental and physical - but also to the stability of millions of people. For all of us independent news organizations, it’s no exception.

We’ve covered everything thrown at us this past year and will continue to do so with your support. We’ve always understood the importance of calling out corruption, regardless of political affiliation.

We need your support in this difficult time. Every reader contribution, no matter the amount, makes a difference in allowing our newsroom to bring you the stories that matter, at a time when being informed is more important than ever. Invest with us.

Make a one-time contribution to Alternet All Access, or click here to become a subscriber. Thank you.

Click to donate by check.

DonateDonate by credit card
Donate by Paypal
{{ post.roar_specific_data.api_data.analytics }}
@2022 - AlterNet Media Inc. All Rights Reserved. - "Poynter" fonts provided by fontsempire.com.